Status:
COMPLETED
Target Attainment of TDM-guided Infusion of Piperacillin/Tazobactam and Cefepim in Critically Ill Patients
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Critical Illness
Antibiotic Toxicity
Eligibility:
All Genders
18+ years
Brief Summary
Although alternative dosing strategies can improve antimicrobial exposure in critically ill patients, the high PK variability in this population means that some may still receive sub-optimal antibioti...
Eligibility Criteria
Inclusion
- Minimun age limits 18 years
- Critically ill patient receiving piperacillin or cefepim administered continuously
Exclusion
- Beta lactam allergy
- Pregnancy
- Age less than 18 years
Key Trial Info
Start Date :
May 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 2 2019
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT04530045
Start Date
May 2 2018
End Date
November 2 2019
Last Update
August 28 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Emmanuel NOVY
Vandœuvre-lès-Nancy, Lorraine, France, 54500
2
Central Hospital
Vandœuvre-lès-Nancy, France, 54500